CD82 and cancer: If SRCC constitute the major dormant cancer population (or one of them), riboflavin fluorescence (or SLC52A1-3), NOTCH1, and CD82, may serve as reliable markers for the clinical assessment of tumor cell dormancy and prediction of relapse.